Searchable abstracts of presentations at key conferences in endocrinology

ea0081p171 | Pituitary and Neuroendocrinology | ECE2022

Efficacy of pasireotide LAR for acromegaly: a long-term real-world monocentric study

Zampetti Benedetta , Isabella Carioni Emanuela , Dalino Ciaramella Paolo , Grossrubatscher Erika , Dallabonzana Daniela , Attanasio Roberto , Cozzi Renato

Patients: Nineteen acromegalic patients (8 females, 21-69 years-old, with macroadenoma, microadenoma or no evidence of pituitary tumor in 15, 2, 2, respectively) resistant to first generation somatostatin analogs (FG-SA) at high doses and/or intolerant to pegvisomant were switched to pasireotide LAR (PasLAR). Eleven had persistent disease after neurosurgery and two had also undergone radiosurgery (12 and 24 months before starting PasLAR). Six complained of acromegalic headache...

ea0070aep143 | Bone and Calcium | ECE2020

Osteocalcin may participate to the bone-parathyroid crosstalk through activation of the calcium-sensing receptor in human parathyroid adenomas

Verdelli Chiara , Stefania Tavanti Giulia , Maggiore Riccardo , Mari Gilberto , Sansoni Veronica , Perego Silvia , Vicentini Leonardo , Dalino Ciaramella Paolo , Lombardi Giovanni , Corbetta Sabrina

Parathyroid glands regulate bone metabolism through PTH, while bone modulates parathyroid function through calcium and FGF23. Bone releases the matrix protein osteocalcin (OC), whose hormone function is increasingly evident. We tested the hypothesis that OC may modulate parathyroid function. The 6 hours-stimulation of human parathyroid cells derived from adenomas (PAds) (n = 5) with γ-carboxylated OC (GlaOC; 40–60 ng/ml) increased the expression levels ...